SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 50% Gains Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (69144)11/21/2008 10:30:11 AM
From: Dale BakerRead Replies (2) of 118717
 
Since I know almost nothing about biotech, I am open to opinions and info from any quarter. I note that DNA has a net cash position of a few bucks per share, so financing is not a problem. But I could see the PE multiple dropping if/when growth tapers off too.

So estimates over $3 per share going forward could mean 60 or 30; and the Roche $89 buyout is losing credibility fast, the market says.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News